The Role of Molecular Diagnostics in the Management of Patients with Gliomas

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009

(2016) Dorothee Gramatzki et al.   CANCER

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma

(2016) Michele Ceccarelli et al.   CELL

Successful Treatment of a ProgressiveBRAFV600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy

(2016) Eudocia Q. Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

(2015) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

(2015) Michael Weller et al.   ACTA NEUROPATHOLOGICA

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities

(2015) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors

(2015) Tali Mazor et al.   CANCER CELL

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

(2015) Kristian W. Pajtler et al.   CANCER CELL

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

(2015) M. Weller et al.   CLINICAL CANCER RESEARCH

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

Integrated genomic characterization of IDH1-mutant glioma malignant progression

(2015) Hanwen Bai et al.   NATURE GENETICS

Highlights from the Literature

(2015) Wolfgang Wick et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012

(2015) Quinn T. Ostrom et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glioma

(2015) Michael Weller et al.   Nature Reviews Disease Primers

Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

(2014) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

(2014) Felix Sahm et al.   ACTA NEUROPATHOLOGICA

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma

(2014) David E. Reuss et al.   ACTA NEUROPATHOLOGICA

Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling

(2014) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

(2014) David Neal Franz et al.   LANCET ONCOLOGY

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

(2014) Michael Weller et al.   LANCET ONCOLOGY

C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymoma

(2014) Matthew Parker et al.   NATURE

A vaccine targeting mutant IDH1 induces antitumour immunity

(2014) Theresa Schumacher et al.   NATURE

Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma

(2014) Rintaro Hashizume et al.   NATURE MEDICINE

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

(2013) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series

(2013) Marc C. Chamberlain   JOURNAL OF NEURO-ONCOLOGY

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Phase 2 trial design in neuro-oncology revisited: a report from the RANO group

(2012) Evanthia Galanis et al.   LANCET ONCOLOGY

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

(2012) Gang Wu et al.   NATURE GENETICS

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

(2011) Genevieve Schindler et al.   ACTA NEUROPATHOLOGICA

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51

(2011) Thomas B. Daniels et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors

(2011) A. B. Lassman et al.   NEURO-ONCOLOGY

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

(2010) Jörg Felsberg et al.   ACTA NEUROPATHOLOGICA

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

(2010) B. Jena et al.   BLOOD

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

MGMTPromoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tandem Duplication Producing a Novel OncogenicBRAFFusion Gene Defines the Majority of Pilocytic Astrocytomas

(2008) David T.W. Jones et al.   CANCER RESEARCH

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE